ArticlePloS one2016
A Prototype Recombinant-Protein Based Chlamydia pecorum Vaccine Results in Reduced Chlamydial Burden and Less Clinical Disease in Free-Ranging Koalas (Phascolarctos cinereus).
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Current status and future directions ofFrontiers in veterinary science · 2026Pooled it
- Adaptive Immunity in Marsupials.Journal of experimental zoology. Part A, Ecological and integrative physiology · 2026Review
- Evaluation of Chlamydia pecorum major outer membrane protein vaccine a management tool in wild koala (Phascolarctos cinereus) populations.Scientific reports · 2025Article
- Dominance of Vaccine-SpecificEcology and evolution · 2025Article
- Epidemiology, Transmission Mode, and Pathogenesis ofAnimals : an open access journal from MDPI · 2024Review
- Immunisation of koalas against Chlamydia pecorum results in significant protection against chlamydial disease and mortality.NPJ vaccines · 2024Article
- Immunohistochemical characterization of the immune cell response during chlamydial infection in the male and female koala (Veterinary pathology · 2024Article
- Koala ocular disease grades are defined by chlamydial load changes and increases in Th2 immune responses.Frontiers in cellular and infection microbiology · 2024Article
- Efficacy of a synthetic peptide Chlamydia pecorum major outer membrane protein vaccine in a wild koala (Phascolarctos cinereus) population.Scientific reports · 2023Article
- Reduction ofVaccine: X · 2023Article
- Susceptibility to a sexually transmitted disease in a wild koala population shows heritable genetic variance but no inbreeding depression.Molecular ecology · 2022Article
- The Koala Immune Response to Chlamydial Infection and Vaccine Development-Advancing Our Immunological Understanding.Animals : an open access journal from MDPI · 2021Review
- Ecological and Evolutionary Challenges for Wildlife Vaccination.Trends in parasitology · 2020Review
- Koala retrovirus epidemiology, transmission mode, pathogenesis, and host immune response in koalas (Phascolarctos cinereus): a review.Archives of virology · 2020Review
- Helping koalas battle disease - Recent advances in Chlamydia and koala retrovirus (KoRV) disease understanding and treatment in koalas.FEMS microbiology reviews · 2020Review
- New technologies in the mix: Assessing N-mixture models for abundance estimation using automated detection data from drone surveys.Ecology and evolution · 2020Article
- Article
- Capturing Complex Vaccine-Immune-Disease Relationships for Free-Ranging Koalas: Higher Chlamydial Loads Are Associated With Less IL17 Expression and More Chlamydial Disease.Frontiers in veterinary science · 2020Article
- Review
- Automated detection of koalas using low-level aerial surveillance and machine learning.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diseases associated with Chlamydia pecorum infection are a major cause of decline in koala populations in Australia. While koalas in care can generally be treated, a vaccine is considered the only option to effectively reduce the threat of infection and disease at the population level. In the current study, we vaccinated 30 free-ranging koalas with a prototype Chlamydia pecorum vaccine consisting of a recombinant chlamydial MOMP adjuvanted with an immune stimulating complex. An additional cohort of 30 animals did not receive any vaccine and acted as comparison controls. Animals accepted into this study were either uninfected (Chlamydia PCR negative) at time of initial vaccination, or infected (C. pecorum positive) at either urogenital (UGT) and/or ocular sites (Oc), but with no clinical signs of chlamydial disease. All koalas were vaccinated/sampled and then re-released into their natural habitat before re-capturing and re-sampling at 6 and 12 months. All vaccinated koalas produced a strong immune response to the vaccine, as indicated by high titres of specific plasma antibodies. The incidence of new infections in vaccinated koalas over the 12-month period post-vaccination was slightly less than koalas in the control group, however, this was not statistically significant. Importantly though, the vaccine was able to significantly reduce the infectious load in animals that were Chlamydia positive at the time of vaccination. This effect was evident at both the Oc and UGT sites and was stronger at 6 months than at 12 months post-vaccination. Finally, the vaccine was also able to reduce the number of animals that progressed to disease during the 12-month period. While the sample sizes were small (statistically speaking), results were nonetheless striking. This study highlights the potential for successful development of a Chlamydia vaccine for koalas in a wild setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.